Compare NXRT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXRT | VALN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.3M | 653.3M |
| IPO Year | 2014 | 2021 |
| Metric | NXRT | VALN |
|---|---|---|
| Price | $21.47 | $6.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $31.00 | $15.50 |
| AVG Volume (30 Days) | ★ 404.9K | 28.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $251,281,000.00 | N/A |
| Revenue This Year | $3.09 | N/A |
| Revenue Next Year | $3.02 | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.13 | $4.75 |
| 52 Week High | $33.34 | $12.23 |
| Indicator | NXRT | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 28.23 | 51.11 |
| Support Level | N/A | $6.29 |
| Resistance Level | $24.77 | $6.60 |
| Average True Range (ATR) | 0.70 | 0.21 |
| MACD | -0.10 | -0.09 |
| Stochastic Oscillator | 1.26 | 21.67 |
NexPoint Residential Trust Inc is a real estate investment trust company. The trust's objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.